[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content
. Author manuscript; available in PMC: 2008 Nov 1.
Published in final edited form as: Nucl Med Biol. 2007 Sep 4;34(8):945–953. doi: 10.1016/j.nucmedbio.2007.07.003

Table 1.

Biodistribution of 68Ga-DOTA-ReCCMSH(Arg11) (0.24 μg) (%ID/g ± SD, n = 5) in C57BL/6 mice bearing day-10 B16/F1 melanoma tumors at 30 min and 2 h. The third group was pretreated with blockade (20 μg DOTA-ReCCMSH(Arg11)) and the fourth group was pretreated with D-lysine.

Tissues 30 min 2 h 2 h with blockade 2 h with D-lysine
blood 4.65 ± 0.84 0.40 ± 0.13 0.63 ± 0.27 0.51 ± 0.17
lung 3.78 ± 0.38 0.40 ± 0.10 0.62 ± 0.21 0.32 ± 0.10
liver 1.34 ± 0.09 0.50 ± 0.11 0.53 ± 0.21 0.45 ± 0.28
spleen 1.34 ± 0.29 0.21 ± 0.04 0.30 ± 0.14 0.27 ± 0.10
kidney 16.50 ± 4.30 6.80 ± 1.72 8.88 ± 2.53 3.17 ± 1.41
muscle 1.16 ± 0.50 0.10 ± 0.03 0.29 ± 0.19 0.08 ± 0.03
heart 2.00 ± 0.41 0.16 ± 0.04 0.30 ± 0.16 0.22 ± 0.11
skin 2.54 ± 0.93 0.31 ± 0.14 0.64 ± 0.11 0.31 ± 0.17
B16/F1 tumor 4.31 ± 1.94 4.25 ± 1.41 0.42 ± 0.05 3.44 ± 1.32